A Roundtable Discussion with Jennifer Doudna, Stephen Hauser & Ehud Isacoff

Over the past decade, neuroscientists have made tremendous breakthroughs in understanding the underlying causes of brain disease. At the same time, CRISPR genome editing has generated new hope for developing treatments for a wide range of unaddressed genetic diseases. Now a group of leading researchers at UC Berkeley, UCSF, and the Innovative Genomics Institute, are bringing these two advancements together to create new, breakthrough therapies for neurological diseases.

In this roundtable discussion, Jennifer Doudna, Stephen Hauser, and Ehud Isacoff will discuss the promise and challenges of creating new therapies for neurological diseases and bringing them to the clinic, as well as the need to develop cures that are accessible and affordable.

Read more about the recently announced Alliance for Therapies in Neuroscience (ATN), a long-term research partnership with Genentech and its parent company, Roche Holding AG, to speed the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system.